1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,690 | 0,840 | 12:36 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | LAEKNA-B (02105): 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| Fr | LAEKNA-B (02105): 2023 ANNUAL REPORT | - | HKEx | ||
| 15.04. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE102 FOR THE TREATMENT OF OBESITY WAS OBTAINED FROM THE U.S. FOOD AND ... | 1 | HKEx | ||
| 26.03. | LAEKNA-B (02105): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 | - | HKEx | ||
| 11.03. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LAE102 FOR THE TREATMENT OF OBESITY TO THE U.S. FOOD AND ... | 1 | HKEx | ||
| 07.03. | LAEKNA-B (02105): DATE OF BOARD MEETING | 1 | HKEx | ||
| 01.03. | LAEKNA-B (02105): LETTER TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS AND REPLY FORM | - | HKEx | ||
| 01.03. | LAEKNA-B (02105): LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS AND REPLY FORM | - | HKEx | ||
| 01.03. | China's Laekna hits 5-week peak on progress of new drug application | 1 | Reuters | ||
| 29.02. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT THE CENTRE FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE INVESTIGATIONAL NEW ... | - | HKEx | ||
| 02.02. | LAEKNA-B (02105): CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE, AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND ... | - | HKEx | ||
| 29.01. | After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial | 16 | FierceBiotech | ||
| 15.01. | LAEKNA-B (02105): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 15.01. | LAEKNA-B (02105): (1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION OF BOARD COMMITTEES; AND (2) APPOINTMENT OF CHIEF FINANCIAL OFFICER | 1 | HKEx | ||
| 04.01. | Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024 | 136 | PR Newswire | Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis.
Derived from the platform, LAE105 is a potentially... ► Artikel lesen | |
| 15.12.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 15.12.2023 | 679 | Xetra Newsboard | The following instruments on XETRA do have their first trading 15.12.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 15.12.2023
Aktien
1 CA02255Q2099 Alvopetro Energy Ltd.
2... ► Artikel lesen | |
| 11.12.23 | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE STUDY RESULTS FROM CORE PRODUCT AFURESERTIB (LAE002) AT THE 2023 SABCS | 2 | HKEx | ||
| 25.08.23 | Laekna, Inc. (2105.HK) Announces Interim Results 2023 | 255 | PR Newswire | For the Phase II pivotal trial of Afuresertib (LAE002) + Paclitaxel for platinum-resistant recurrent ovarian cancer (PROFECTOR-II), the patients were fully enrolled and the topline data is expected... ► Artikel lesen | |
| 29.06.23 | Laekna, Inc: Laekna, a Biotechnology Company in China, Listed on the Main Board of the Hong Kong Stock Exchange | 470 | JCN Newswire | HONG KONG, June 29, 2023 - (ACN Newswire) - A biotechnology company in China - Laekna, Inc. (stock code: 2105.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,840 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen | |
| MORPHOSYS | 66,15 | -0,08 % | Novartis-Übernahme läuft: Verlust verzehnfacht: Morphosys muss "Karten auf den Tisch legen" | © Foto: Sven Hoppe/dpaDie geplante Übernahme durch Novartis sorgt für hohe Kosten und lassen die Verluste bei Morphosys explodieren. Für Unruhe sorgt ein Fachartikel zu Sicherheit des Krebsmedikaments... ► Artikel lesen | |
| ARVINAS | 32,480 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,740 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,310 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| EVOTEC | 9,950 | +2,16 % | Herbe Enttäuschung bei Evotec, Tesla lenkt erfolgreich ab, Nvidia bei Analysten noch immer gefragt und bei Nel ASA wird die Hoffnung dünner! | Investments in Aktien sind stets eine Investition in die Zukunft. Dementsprechend legen die Anleger natürlich ihren Fokus auf den Ausblick der börsennotierten Unternehmen. Wie sehr jener die Kurse beeinflussen... ► Artikel lesen | |
| QIAGEN | 39,800 | +1,84 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
| COGENT BIOSCIENCES | 6,910 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor | WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 28,100 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| NUVALENT | 70,65 | 0,00 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 17,680 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| ARCELLX | 52,16 | 0,00 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| RELAY THERAPEUTICS | 6,660 | +2,15 % | Relay Therapeutics, Inc.: Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024 | ||
| CYTOMX THERAPEUTICS | 4,068 | +165,54 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 19,010 | 0,00 % | Edgewise Therapeutics: Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies | Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten... ► Artikel lesen |
LAEKNA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +8,27 % bei einem Aktienkurs von 0,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
